CureDuchenne Invests $1M in Gennao Bio’s Effort to Find Therapies

CureDuchenne Invests $1M in Gennao Bio’s Effort to Find Therapies

315247

CureDuchenne Invests $1M in Gennao Bio’s Effort to Find Therapies

Genetic medicines company Gennao Bio will use a $1 million CureDuchenne Ventures investment to help expand its gene monoclonal antibody (GMAB) platform technology, which is now applied to rare muscle disorders, including Duchenne muscular dystrophy (DMD). The initial focus of the nonviral delivery system Gennao Bio is developing had been significant unmet needs in oncology. CureDuchenne’s commitment, which is part of Gennao Bio’s Series A funding extension, will allow it to extend that focus to…

You must be logged in to read/download the full post.